|
1
|
Carver BS, Chapinski C, Wongvipat J,
Hieronymus H, Chen Y, Chandarlapaty S, Arora VK, Le C, Koutcher J,
Scher H, et al: Reciprocal feedback regulation of PI3K and androgen
receptor signaling in PTEN-deficient prostate cancer. Cancer Cell.
19:575–586. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Rastinehad AR, Baccala AA Jr, Chung PH,
Proano JM, Kruecker J, Xu S, Locklin JK, Turkbey B, Shih J,
Bratslavsky G, et al: D'Amico risk stratification correlates with
degree of suspicion of prostate cancer on multiparametric magnetic
resonance imaging. J Urol. 185:815–820. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brawley OW: Prostate cancer epidemiology
in the United States. World J Urol. 30:195–200. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Feng J, Zhang X, Zhu H, Wang X, Ni S and
Huang J: FoxQ1 overexpression influences poor prognosis in
non-small cell lung cancer, associates with the phenomenon of EMT.
PLoS One. 7:e399372012. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Gao M, Shih IeM and Wang TL: The role of
forkhead box Q1 transcription factor in ovarian epithelial
carcinomas. Int J Mol Sci. 13:13881–13893. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Qin J, Xu Y, Li X, Wu Y, Zhou J, Wang G
and Chen L: Effects of lentiviral-mediated Foxp1 and Foxq1 RNAi on
the hepatocarcinoma cell. Exp Mol Pathol. 96:1–8. 2014. View Article : Google Scholar
|
|
7
|
Zhang H, Meng F, Liu G, Zhang B, Zhu J, Wu
F, Ethier SP, Miller F and Wu G: Forkhead transcription factor
foxq1 promotes epithelial-mesenchymal transition and breast cancer
metastasis. Cancer Res. 71:1292–1301. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Feuerborn A, Srivastava PK, Küffer S,
Grandy WA, Sijmonsma TP, Gretz N, Brors B and Gröne HJ: The
Forkhead factor FoxQ1 influences epithelial differentiation. J Cell
Physiol. 226:710–719. 2011. View Article : Google Scholar
|
|
9
|
Candelario J, Chen LY, Marjoram P, Reddy S
and Comai L: A filtering strategy identifies FOXQ1 as a potential
effector of lamin A dysfunction. Aging (Albany, NY). 4:567–577.
2012. View Article : Google Scholar
|
|
10
|
Liang SH, Yan XZ, Wang BL, Jin HF, Yao LP,
Li YN, Chen M, Nie YZ, Wang X, Guo XG, et al: Increased expression
of FOXQ1 is a prognostic marker for patients with gastric cancer.
Tumour Biol. 34:2605–2609. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Christensen J, Bentz S, Sengstag T,
Shastri VP and Anderle P: FOXQ1, a novel target of the Wnt pathway
and a new marker for activation of Wnt signaling in solid tumors.
PLoS One. 8:e600512013. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Xiang XJ, Deng J, Liu YW, Wan LY, Feng M,
Chen J and Xiong JP: miR-1271 inhibits cell proliferation, invasion
and EMT in gastric cancer by targeting FOXQ1. Cell Physiol Biochem.
36:1382–1394. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Yuan H, Kajiyama H, Ito S, Yoshikawa N,
Hyodo T, Asano E, Hasegawa H, Maeda M, Shibata K, Hamaguchi M, et
al: ALX1 induces snail expression to promote
epithelial-to-mesenchymal transition and invasion of ovarian cancer
cells. Cancer Res. 73:1581–1590. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Drasin DJ, Robin TP and Ford HL: Breast
cancer epithelial-to-mesenchymal transition: Examining the
functional consequences of plasticity. Breast Cancer Res.
13:2262011. View
Article : Google Scholar : PubMed/NCBI
|
|
15
|
Qi X, Li J, Zhou C, Lv C and Tian M:
miR-142-3p suppresses SOCS6 expression and promotes cell
proliferation in nasopharyngeal carcinoma. Cell Physiol Biochem.
36:1743–1752. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Sun HT, Cheng SX, Tu Y, Li XH and Zhang S:
FoxQ1 promotes glioma cells proliferation and migration by
regulating NRXN3 expression. PLoS One. 8:e556932013. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang W, He S, Ji J, Huang J, Zhang S and
Zhang Y: The prognostic significance of FOXQ1 oncogene
overexpression in human hepatocellular carcinoma. Pathol Res Pract.
209:353–358. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Pei Y, Wang P, Liu H, He F and Ming L:
FOXQ1 promotes esophageal cancer proliferation and metastasis by
negatively modulating CDH1. Biomed Pharmacother. 74:89–94. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Feng J, Xu L, Ni S, Gu J, Zhu H, Wang H,
Zhang S, Zhang W and Huang J: Involvement of FoxQ1 in NSCLC through
regulating EMT and increasing chemosensitivity. Oncotarget.
5:9689–9702. 2014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Su L, Liu X, Chai N, Lv L, Wang R, Li X,
Nie Y, Shi Y and Fan D: The transcription factor FOXO4 is
down-regulated and inhibits tumor proliferation and metastasis in
gastric cancer. BMC Cancer. 14:3782014. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Kaneda H, Arao T, Tanaka K, Tamura D,
Aomatsu K, Kudo K, Sakai K, De Velasco MA, Matsumoto K, Fujita Y,
et al: FOXQ1 is overexpressed in colorectal cancer and enhances
tumorigenicity and tumor growth. Cancer Res. 70:2053–2063. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Zhu Z, Zhu Z, Pang Z, Xing Y, Wan F, Lan D
and Wang H: Short hairpin RNA targeting FOXQ1 inhibits invasion and
metastasis via the reversal of epithelial-mesenchymal transition in
bladder cancer. Int J Oncol. 42:1271–1278. 2013.PubMed/NCBI
|
|
23
|
Zhang J, Li W, Dai S, Tai X, Jia J and Guo
X: FOXQ1 is overexpressed in laryngeal carcinoma and affects cell
growth, cell cycle progression and cell invasion. Oncol Lett.
10:2499–2504. 2015.PubMed/NCBI
|
|
24
|
Kutlar A, Ataga K, Reid M, Vichinsky EP,
Neumayr L, Blair-Britt L, Labotka R, Glass J, Keefer JR, Wargin WA,
et al: A phase 1/2 trial of HQK-1001, an oral fetal globin inducer,
in sickle cell disease. Am J Hematol. 87:1017–1021. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Yu Y, Wang J, Khaled W, Burke S, Li P,
Chen X, Yang W, Jenkins NA, Copeland NG, Zhang S, et al: Bcl11a is
essential for lymphoid development and negatively regulates p53. J
Exp Med. 209:2467–2483. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Staszewski O, Baker RE, Ucher AJ, Martier
R, Stavnezer J and Guikema JE: Activation-induced cytidine
deaminase induces reproducible DNA breaks at many non-Ig loci in
activated B cells. Mol Cell. 41:232–242. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Tao H, Ma X, Su G, Yin J, Xie X, Hu C,
Chen Z, Tan D, Xu Z, Zheng Y, et al: BCL11A expression in acute
myeloid leukemia. Leuk Res. 41:71–75. 2016. View Article : Google Scholar
|
|
28
|
Jiang BY, Zhang XC, Su J, Meng W, Yang XN,
Yang JJ, Zhou Q, Chen ZY, Chen ZH, Xie Z, et al: BCL11A
overexpression predicts survival and relapse in non-small cell lung
cancer and is modulated by microRNA-30a and gene amplification. Mol
Cancer. 12:612013. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Wade M, Li YC and Wahl GM: MDM2, MDMX and
p53 in oncogenesis and cancer therapy. Nat Rev Cancer. 13:83–96.
2013. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Li T, Kon N, Jiang L, Tan M, Ludwig T,
Zhao Y, Baer R and Gu W: Tumor suppression in the absence of
p53-mediated cell-cycle arrest, apoptosis, and senescence. Cell.
149:1269–1283. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Wan Y, Wu W, Yin Z, Guan P and Zhou B:
MDM2 SNP309, gene-gene interaction, and tumor susceptibility: An
updated meta-analysis. BMC Cancer. 11:2082011. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Zhang J, Sun Q, Zhang Z, Ge S, Han ZG and
Chen WT: Loss of microRNA-143/145 disturbs cellular growth and
apoptosis of human epithelial cancers by impairing the MDM2-p53
feedback loop. Oncogene. 32:61–69. 2013. View Article : Google Scholar
|
|
33
|
Li Q and Lozano G: Molecular pathways:
Targeting Mdm2 and Mdm4 in cancer therapy. Clin Cancer Res.
19:34–41. 2013. View Article : Google Scholar :
|
|
34
|
Zhang YY and Zhou LM: Sirt3 inhibits
hepatocellular carcinoma cell growth through reducing Mdm2-mediated
p53 degradation. Biochem Biophys Res Commun. 423:26–31. 2012.
View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Tovar C, Higgins B, Kolinsky K, Xia M,
Packman K, Heimbrook DC and Vassilev LT: MDM2 antagonists boost
antitumor effect of androgen withdrawal: Implications for therapy
of prostate cancer. Mol Cancer. 10:492011. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Welsh JB, Sapinoso LM, Su AI, Kern SG,
Wang-Rodriguez J, Moskaluk CA, Frierson HF Jr and Hampton GM:
Analysis of gene expression identifies candidate markers and
pharmacological targets in prostate cancer. Cancer Res.
61:5974–5978. 2001.PubMed/NCBI
|
|
37
|
Shiozawa Y, Pedersen EA, Havens AM, Jung
Y, Mishra A, Joseph J, Kim JK, Patel LR, Ying C, Ziegler AM, et al:
Human prostate cancer metastases target the hematopoietic stem cell
niche to establish footholds in mouse bone marrow. J Clin Invest.
121:1298–1312. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
38
|
Xia L, Huang W, Tian D, Zhang L, Qi X,
Chen Z, Shang X, Nie Y and Wu K: Forkhead box Q1 promotes
hepatocellular carcinoma metastasis by transactivating ZEB2 and
VersicanV1 expression. Hepatology. 59:958–973. 2014. View Article : Google Scholar
|
|
39
|
Bao B, Azmi AS, Aboukameel A, Ahmad A,
Bolling-Fischer A, Sethi S, Ali S, Li Y, Kong D, Banerjee S, et al:
Pancreatic cancer stem-like cells display aggressive behavior
mediated via activation of FoxQ1. J Biol Chem. 289:14520–14533.
2014. View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Qiao Y, Jiang X, Lee ST, Karuturi RK, Hooi
SC and Yu Q: FOXQ1 regulates epithelial-mesenchymal transition in
human cancers. Cancer Res. 71:3076–3086. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Peng XH, Huang HR, Lu J, Liu X, Zhao FP,
Zhang B, Lin SX, Wang L, Chen HH, Xu X, et al: miR-124 suppresses
tumor growth and metastasis by targeting Foxq1 in nasopharyngeal
carcinoma. Mol Cancer. 13:1862014. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Costa FC, Fedosyuk H, Neades R, de Los
Rios JB, Barbas CF III and Peterson KR: Induction of fetal
hemoglobin in vivo mediated by a synthetic γ-globin zinc finger
activator. Anemia. 2012:5078942012. View Article : Google Scholar
|
|
43
|
Esteghamat F, Gillemans N, Bilic I, van
den Akker E, Cantù I, van Gent T, Klingmüller U, van Lom K, von
Lindern M, Grosveld F, et al: Erythropoiesis and globin switching
in compound Klf1:Bcl11a mutant mice. Blood. 121:2553–2562. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
44
|
Liu P, Keller JR, Ortiz M, Tessarollo L,
Rachel RA, Nakamura T, Jenkins NA and Copeland NG: Bcl11a is
essential for normal lymphoid development. Nat Immunol. 4:525–532.
2003. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Kadoch C, Hargreaves DC, Hodges C, Elias
L, Ho L, Ranish J and Crabtree GR: Proteomic and bioinformatic
analysis of mammalian SWI/SNF complexes identifies extensive roles
in human malignancy. Nat Genet. 45:592–601. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
46
|
Khaled WT, Choon Lee S, Stingl J, Chen X,
Raza Ali H, Rueda OM, Hadi F, Wang J, Yu Y, Chin SF, et al: BCL11A
is a triple-negative breast cancer gene with critical functions in
stem and progenitor cells. Nat Commun. 6:59872015. View Article : Google Scholar : PubMed/NCBI
|
|
47
|
Bond GL, Hu W, Bond EE, Robins H, Lutzker
SG, Arva NC, Bargonetti J, Bartel F, Taubert H, Wuerl P, et al: A
single nucleotide polymorphism in the MDM2 promoter attenuates the
p53 tumor suppressor pathway and accelerates tumor formation in
humans. Cell. 119:591–602. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
48
|
Jones SN, Hancock AR, Vogel H, Donehower
LA and Bradley A: Overexpression of Mdm2 in mice reveals a
p53-independent role for Mdm2 in tumorigenesis. Proc Natl Acad Sci
USA. 95:15608–15612. 1998. View Article : Google Scholar : PubMed/NCBI
|
|
49
|
Klein C and Vassilev LT: Targeting the
p53-MDM2 interaction to treat cancer. Br J Cancer. 91:1415–1419.
2004.PubMed/NCBI
|
|
50
|
Zhang Z, Li M, Wang H, Agrawal S and Zhang
R: Antisense therapy targeting MDM2 oncogene in prostate cancer:
Effects on proliferation, apoptosis, multiple gene expression, and
chemotherapy. Proc Natl Acad Sci USA. 100:11636–11641. 2003.
View Article : Google Scholar : PubMed/NCBI
|
|
51
|
Wang W, Zhang X, Qin JJ, Voruganti S, Nag
SA, Wang MH, Wang H and Zhang R: Natural product ginsenoside
25-OCH3-PPD inhibits breast cancer growth and metastasis through
down-regulating MDM2. PLoS One. 7:e415862012. View Article : Google Scholar : PubMed/NCBI
|
